Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Strong Trading Volume - Here's What Happened

Key Points

• Fresenius SE & Co. experienced a 227% increase in trading volume, with approximately 159,479 shares traded on Thursday, compared to 48,755 shares the previous session.
• Analysts, including Morgan Stanley, have given Fresenius SE & Co. a consensus rating of "Buy", indicating positive growth prospects for the company.
• The company reported a quarterly earnings per share of $0.24, surpassing the consensus estimate of $0.22, alongside a revenue of $6.48 billion, exceeding expectations of $5.83 billion.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) shares saw unusually-strong trading volume on Thursday . Approximately 159,479 shares were traded during trading, an increase of 227% from the previous session's volume of 48,755 shares.The stock last traded at $13.77 and had previously closed at $13.88.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley restated an "overweight" rating on shares of Fresenius SE & Co. in a research report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. Based on data from MarketBeat, Fresenius SE & Co. presently has a consensus rating of "Buy".

Fresenius SE & Co. Trading Up 0.1%

The company has a current ratio of 1.31, a quick ratio of 1.00 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $31.05 billion, a price-to-earnings ratio of 26.23 and a beta of 0.83. The company has a fifty day moving average of $13.71 and a 200-day moving average of $12.54.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.02. The business had revenue of $6.48 billion for the quarter, compared to analysts' expectations of $5.83 billion. Fresenius SE & Co. had a return on equity of 9.33% and a net margin of 5.09%. As a group, equities research analysts anticipate that Fresenius SE & Co. will post 0.79 earnings per share for the current fiscal year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.